Online citations, reference lists, and bibliographies.
← Back to Search

Metabolic Tracing Of Monoacylglycerol Acyltransferase-2 Activity In vitro And In vivo.

J. Qi, W. Lang, M. Connelly, Fuyong Du, Y. Liang, G. Caldwell, Tonya Martin, M. K. Hansen, G. Kuo, M. Gaul, A. Pocai, S. Lee
Published 2017 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Monoacylglycerol acyltransferase 2 (MGAT2) catalyzes the synthesis of diacylglycerol (DAG) from free fatty acids (FFA) and sn-monoacylglycerol (MG), the two major hydrolysis products of dietary fat. To demonstrate MGAT2-mediated cellular activity of triglyceride (TG) synthesis, we utilized 1-oleoyl-glycerol-d5 as a substrate to trace MGAT2-driven 1-oleoyl-glycerol-d5 incorporation into TG in HEK293 cells stably expressing human MGAT2. The oleoyl-glycerol-d5 incorporated major TG species were then quantified by liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS) in a 96-well format. Conventional MGAT2 target-engagement in vivo assays measure the elevation of total plasma TG by orally dosing a bolus of TG oil. We developed a novel LC/ESI/MS/MS-based fat absorption assay to assess the ability of MGAT2 inhibitors to inhibit fat absorption in CD1 mice by a meal tolerance test consisting of a mixture of liquid Boost plus® and 0.59 g/kg U13C-TG oil. The newly resynthesized plasma heavy TGs containing three 13C in the glycerol backbone and two U13C-acyl-chains, which represented the digested, absorbed and resynthesized TGs, were then quantitated by LC/ESI/MS/MS. With this assay, we identified a potent MGAT2 inhibitor that blocked MGAT2-mediated activity in vitro and in vivo. The use of 1-oleoyl-glycerol-d5 and U13C-TG oil followed by LC/ESI/MS/MS detection of stable-isotopic labeled DAG, TG, or glycerol provides a wide range of applications to study pathophysiological regulation of the monoacylglycerol pathway and MGAT2 activity.
This paper references
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat
S. J. Smith (2000)
Kinetics of the two-step hydrolysis of triacylglycerol by pancreatic lipases.
A. Lykidis (1995)
Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes
Yasuhiro Hayashi (2014)
J. G. Barlind (2016)
Hepatic mono - acylglycerol O - acyltransferase 1 as a promising therapeutic target for steatosis , obesity , and type 2 diabetes
E. Suemitsu
Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.
K. Sato (2015)
Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS[S]
Joelle M. Onorato (2015)
High-content assays for evaluating cellular and hepatic diacylglycerol acyltransferase activity
J. Qi (2010)
MGAT2 deficiency ameliorates high-fat diet-induced obesity and insulin resistance by inhibiting intestinal fat absorption in mice
Takuma Tsuchida (2012)
C. Okuma (2015)
Identi fi cation and design of a novel series of MGAT 2 inhibitors
J. G. Barlind
JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity.
Chihiro Okuma (2015)
Intestine-specific Deletion of Acyl-CoA:Monoacylglycerol Acyltransferase (MGAT) 2 Protects Mice from Diet-induced Obesity and Glucose Intolerance*
D. Nelson (2014)
C. Okuma (2015)
Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding
C. E. Yen (2009)
Hepatic mono - acylglycerol O - acyltransferase 1 as a promising therapeutic target for steatosis , obesity , and type 2 diabetes
E. Suemitsu
Mai S
J. Qi (2012)
C. L. Yen (2009)
Adult-onset deficiency of acyl CoA:monoacylglycerol acyltransferase 2 protects mice from diet-induced obesity and glucose intolerance[S]
T. Banh (2015)
Identification and design of a novel series of MGAT2 inhibitors.
Jonas G Barlind (2013)
JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
Chihiro Okuma (2015)
Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice
A. M. Hall (2014)
G.G. Stokes (1890)
The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2
J. Qi (2012)
Identi fi cation and design of a novel series of MGAT 2 inhibitors
J. G. Barlind
Enzymes of glycerolipid synthesis in eukaryotes.
R. Bell (1980)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar